Ranbaxy, India's leading pharma giant with consolidated net sales of Rs.12,250 crore and a subsidiary of Daiichi Sankyo of Japan, has successfully completed 20 years in Russia. It established its operations in the Russian market in 1993 with the launch of its key brand, Cifran. Since then, it has grown to become a No. 1 player with a market share of 15.4 per cent in the represented market segment in Russia.

Ranbaxy has operations in 56 regions in Russia and has built strong equity with its customers. It has a portfolio of products covering anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology segments. So far, it has registered 51 drugs in the Russian Federation and commercialised 72 SKU's. Its leading brands in Russia includes ketanov, coldact, faringosept, cifran, pylobact and fenules.

Arun Sawhney, CEO and managing director, said, “Ranbaxy was one of the first pharmaceutical companies from India to set up operations in Russia. We have been providing high quality, affordable generic medicines to the citizens of Russia for the last two decades, thereby supporting the Government to bring down healthcare costs. We remain committed to the Russian market and will continue to operate from the paradigm of quality and patients first.”

Aman Khanna, country head of Russia, said, “Over the years, Ranbaxy has established itself a preferred generic pharmaceutical company in Russia. In the coming years, we look at further expanding our product portfolio to include value added and innovator products from our parent company, Daiichi Sankyo. We are working closely in partnership with regional Govoernments in the line with the Russia Pharma, 2020 Healthcare Plan.”

The Russian pharmaceutical market is estimated at around US$ 20 billion growing at a CAGR of around 11 per cent. The retail/out of pocket market contributes around 66 per cent to the total market. The Federal Government in Russia is committed towards the improvement of the pharma industry with the launch of Russian Pharma 2020 strategy under which the government is encouraging pharma players to carry out heavy local investment in infrastructure, quality improvement programmes, clinical trials hubs and training for health care professionals.